Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference
January 14, 2015 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the Eleventh Annual Noble Financial Capital Markets Investor Conference in Sandpiper Bay,...
Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache
January 09, 2015 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201, which is being...
Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
January 06, 2015 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has received written guidance from the U.S. Food and Drug Administration (FDA) on its Phase 3 clinical...
Tonix Pharmaceuticals to Present at the LD Micro Investor Conference
November 25, 2014 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the LD Micro Main Event VII Conference in Los Angeles, CA. Seth Lederman, M.D., Tonix's...
Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results
November 10, 2014 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced its financial results for the quarter ended September 30, 2014.
"In September, we announced...
Tonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache
October 21, 2014 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia
September 29, 2014 06:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced top line results of the Phase 2b BESTFIT (BEdtime Sublingual TNX-102 SL as Fibromyalgia...
Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference
September 19, 2014 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 19, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 21st Annual BioCentury NewsMakers in the Biotech Industry conference on Friday,...
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
September 03, 2014 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, will...
Tonix Pharmaceuticals Announces Transfer to the NASDAQ Global Market
August 11, 2014 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, is...